Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oric Pharmaceuticals Inc.

5.10
-0.0900-1.73%
Pre-market: 5.740.6400+12.55%04:46 EDT
Volume:362.90K
Turnover:1.85M
Market Cap:362.24M
PE:-2.78
High:5.17
Open:5.08
Low:4.91
Close:5.19
Loading ...

Oric Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
07 Feb

Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Trial Data and Market Projections

TIPRANKS
·
06 Feb

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
28 Jan

Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Oric Pharmaceuticals: Promising Clinical Outcomes and Strategic Advancements Support Buy Rating

TIPRANKS
·
13 Jan

Oric Pharmaceuticals trial results ‘highly encouraging,’ says H.C. Wainwright

TIPRANKS
·
13 Jan

BRIEF-ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114

Reuters
·
13 Jan

Oric Pharmaceuticals sees cash runway into late 2026

TIPRANKS
·
13 Jan

Oric Pharmaceuticals announces clinical supply agreement with Janssen

TIPRANKS
·
13 Jan

Oric Pharmaceuticals Inc: Cash and Investments Expected to Fund Operating Plan Into Late 2026

THOMSON REUTERS
·
13 Jan

Oric Pharmaceuticals Inc - to Initiate Phase 1B Trial for Oric-114 in Q1 2025

THOMSON REUTERS
·
13 Jan

Oric Pharmaceuticals Inc - Expects to Report Initial Trial Data in Mid-2026

THOMSON REUTERS
·
13 Jan

Oric Pharmaceuticals Inc - Enters Supply Agreement With Janssen to Evaluate Oric-114

THOMSON REUTERS
·
13 Jan

Oric Pharmaceuticals Announces Clinical Supply Agreement to Evaluate Oric-114 in Combination With Amivantamab for the First-Line Treatment of Nsclc With Egfr Exon 20 Insertion Mutations

THOMSON REUTERS
·
13 Jan

Oric Pharmaceuticals Inc - to Conduct and Sponsor Trial; J&J to Provide Sc Amivantamab

THOMSON REUTERS
·
13 Jan

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

GlobeNewswire
·
13 Jan

Stifel Nicolaus Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

TIPRANKS
·
09 Jan

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Jan

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Simply Wall St.
·
12 Dec 2024

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
26 Nov 2024